# US 2026/0256902 A1 · A vaccine for protecting a pregnant swine against african swine fever

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0256902 A1
- Document ID: US20260256902A1
- Status: Published application
- Kind: A1
- Application number: 19/162,985
- Filed: 2024-03-15
- Published: 2026-09-03
- Earliest claimed: 2023-03-16
- Assignees: Intervet Inc.
- Applicants: Intervet Inc.
- Inventors: Erwin VAN DEN BORN; Jui JOSHI
- Web page: https://patentgrep.com/patent/US20260256902A1

## CPC

- A61K 39/12: Viral antigens
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 31/20: for DNA viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/552: {Veterinary vaccine}
- C12N 2710/12021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/12034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/12062: by genetic engineering
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention pertains to a live attenuated African swine fever virus Georgia 2007 (ASFV-G) Δ9GL/ΔUK strain for use in a vaccine for protecting a pregnant swine against an infection with African swine fever virus (ASFV) by administering the vaccine comprising the live attenuated ASFV-G-Δ9GL/ΔUK strain to the pregnant swine.

## Claims

### Claim 1

A method for protecting a pregnant swine against an infection with African swine fever virus (ASFV), comprising administering to a pregnant swine a vaccine comprising live attenuated African swine fever virus Georgia 2007 (ASFV-G)-Δ9GL/ΔUK strain.

### Claim 2 (depends on 1)

The method of claim 1, characterised in that the vaccine is administered to the pregnant swine in the second half of gestation.

### Claim 3 (depends on 1)

The method of claim 1, wherein the vaccine is administered to the pregnant swine in the last third of gestation.

### Claim 4 (depends on 1)

The method of claim 1, wherein the vaccine is administered to the pregnant swine in a period of 5-20 days before the expected date of farrowing of the pregnant swine.

### Claim 5 (depends on 1)

The method of claim 1, wherein the vaccine is administered once during gestation or in a prime and boost regimen to the pregnant swine.

### Claim 6 (depends on 1)

The method of claim 1, wherein the vaccine is administered intramuscularly, intradermally or orally.

### Claim 7 (depends on 1)

The method of claim 1, wherein the vaccine is administered with a dose of the ASFV-G-Δ9GL/ΔUK strain of at least 102 TCID50 per administration.

### Claim 8 (depends on 1)

The method of claim 1, wherein the vaccine is administered with a dose of the ASFV-G-Δ9GL/ΔUK strain between 102 TCID50 and 106 TCID50 per administration.

### Claim 9

A live attenuated African swine fever virus Georgia 2007 (ASFV-G) Δ9GL/ΔUK strain for use in the manufacture of a vaccine for the protection of a pregnant swine against an infection with African swine fever virus.

### Claim 10

(canceled)